Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients With Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02273752
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:18.208610+00:00
Published At
2017-02-03T00:00:00+00:00
Record Updated At
2017-02-03
Results Posted At
2017-02-03
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Estrogen Receptor-positive Breast Cancer", "Gastrinoma", "Glucagonoma", "HER2-negative Breast Cancer", "Insulinoma", "Mucositis", "Oral Complications", "Pancreatic Polypeptide Tumor", "Progesterone Receptor-positive Breast Cancer", "Recurrent Breast Cancer", "Recurrent Islet Cell Carcinoma", "Recurrent Renal Cell Cancer", "Somatostatinoma", "Stage III Renal Cell Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Renal Cell Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2017-02-03"
protocolSection.identificationModule.nctId
"NCT02273752"
protocolSection.identificationModule.officialTitle
"Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients With Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2017-02-03"

Study condition terms

  • Estrogen Receptor-positive Breast Cancer (protocolSection.conditionsModule.conditions)
  • Gastrinoma (protocolSection.conditionsModule.conditions)
  • Glucagonoma (protocolSection.conditionsModule.conditions)
  • HER2-negative Breast Cancer (protocolSection.conditionsModule.conditions)
  • Insulinoma (protocolSection.conditionsModule.conditions)
  • Mucositis (protocolSection.conditionsModule.conditions)
  • Oral Complications (protocolSection.conditionsModule.conditions)
  • Pancreatic Polypeptide Tumor (protocolSection.conditionsModule.conditions)
  • Progesterone Receptor-positive Breast Cancer (protocolSection.conditionsModule.conditions)
  • Recurrent Breast Cancer (protocolSection.conditionsModule.conditions)
  • Recurrent Islet Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Renal Cell Cancer (protocolSection.conditionsModule.conditions)
  • Somatostatinoma (protocolSection.conditionsModule.conditions)
  • Stage III Renal Cell Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIA Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Renal Cell Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.